Breaking News

You are here » Indian-Commodity  :  IPO  :  Mishra Dhatu Nigam files DRHP with SEBI for IPO

18-Jan2018

Mishra Dhatu Nigam files DRHP with SEBI for IPO

State-owned Mishra Dhatu Nigam has filed draft red herring prospectus (DRHP) with the markets regulator Securities and Exchange Board of India (SEBI) to float its initial public offering (IPO). The public offer will comprise a sale of up to 46,835,000 equity shares, or 25% stake, by the company's promoter.

The objects of the Offer is to achieve the benefits of listing the Equity Shares on the Stock Exchanges. SBI Capital Markets and IDBI Capital Markets and Securities are book running lead managers to the issue.

Mishra Dhatu Nigam (MIDHANI) manufactures advanced metals and alloys. The company produces super, titanium, and electrical alloys, as well as special purpose steels.


Related News

View all news

Spandana Sphoorty gets SEBI's nod for IPO

Spandana Sphoorty Financial has received markets regulator Securities and Exchange Board of India's (SEBI) approval to raise funds through an initial public offering (IPO). The IPO consists of fresh issue......

Bharat Hotels gets SEBI's approval for IPO

Bharat Hotels has received markets regulator Securities and Exchange Board of India's (SEBI) approval to raise funds through an initial public offering (IPO). The IPO comprises sale of fresh equity shares......

Chartered Speed files DRHP with SEBI for public issue

Fleet bus operators Chartered Speed has filed draft red herring prospectus (DRHP) with the market regulator Securities and Exchange Board of India (SEBI) to raise an estimated Rs 273 crore through an Initial......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......